Chromosomal integration Random recombination

One feature of the latent infection is that AAV is integrated as a stable proviras that preferentially targets the q.l3.4-ter arm of chromosome 19 (23). This property of site-specific integration is the source of considerable appeal for a vector to be used in gene therapy, as it avoids the problem of insertional mutagenesis. This stands in contrast to the retroviral vectors where insertion is a random event. However, it is not clear that the recombinant AAV vectors consistently retain the ability for site-specific integration. 

---